Nu Skin Enterprises, Inc. (NUS) stock
NUSNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/3069% below fair value
$4.01+0.12 (+3.08%)
Close on Nov 12, 2026Market cap $195.19MP/E –Yield –
Nu Skin Enterprises ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Nu Skin Enterprises's ebitda for the twelve months ending Sep 30, 2026 was $23.49M, down 48.1% year over year. For fiscal 2025 it was $118.02M. Over ten years it grew -9.4% a year on average. The highest annual figure on record is $589.04M in fiscal 2013.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $118.02M | – |
| FY2024 | Dec 31, 2024 | -$81.78M | -168.6% |
| FY2023 | Dec 31, 2023 | $119.19M | -35.0% |
| FY2022 | Dec 31, 2022 | $183.35M | -40.9% |
| FY2021 | Dec 31, 2021 | $310.31M | -6.4% |
| FY2020 | Dec 31, 2020 | $331.56M | -3.6% |
| FY2019 | Dec 31, 2019 | $344.08M | +6.2% |
| FY2018 | Dec 31, 2018 | $323.86M | -6.4% |
| FY2017 | Dec 31, 2017 | $346.05M | +14.0% |
| FY2016 | Dec 31, 2016 | $303.50M | -4.0% |
| FY2015 | Dec 31, 2015 | $316.07M | -22.4% |
| FY2014 | Dec 31, 2014 | $407.11M | -30.9% |
| FY2013 | Dec 31, 2013 | $589.04M | +57.4% |
| FY2012 | Dec 31, 2012 | $374.26M | +40.4% |
| FY2011 | Dec 31, 2011 | $266.59M | +8.1% |
| FY2010 | Dec 31, 2010 | $246.68M | +39.9% |
| FY2009 | Dec 31, 2009 | $176.27M | +13.1% |
| FY2008 | Dec 31, 2008 | $155.82M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $17.62M | -47.8% |
| Q2 FY2026 | Jun 30, 2026 | -$46.66M | -206.5% |
| Q1 FY2026 | Mar 31, 2026 | $16.37M | +280.4% |
| Q4 FY2025 | Dec 31, 2025 | $36.16M | – |
| Q3 FY2025 | Sep 30, 2025 | $33.73M | -5.1% |
| Q2 FY2025 | Jun 30, 2025 | $43.83M | – |
| Q1 FY2025 | Mar 31, 2025 | $4.30M | -84.2% |
| Q4 FY2024 | Dec 31, 2024 | -$36.63M | -205.7% |
| Q3 FY2024 | Sep 30, 2024 | $35.55M | – |
| Q2 FY2024 | Jun 30, 2024 | -$107.95M | -280.9% |
| Q1 FY2024 | Mar 31, 2024 | $27.26M | -17.5% |
| Q4 FY2023 | Dec 31, 2023 | $34.65M | -24.7% |
| Q3 FY2023 | Sep 30, 2023 | -$8.17M | – |
| Q2 FY2023 | Jun 30, 2023 | $59.67M | -15.0% |
| Q1 FY2023 | Mar 31, 2023 | $33.05M | -52.3% |
| Q4 FY2022 | Dec 31, 2022 | $46.03M | +18.7% |
| Q3 FY2022 | Sep 30, 2022 | -$2.11M | -102.5% |
| Q2 FY2022 | Jun 30, 2022 | $70.16M | -33.2% |
| Q1 FY2022 | Mar 31, 2022 | $69.28M | -14.7% |
| Q4 FY2021 | Dec 31, 2021 | $38.78M | -63.9% |
| Q3 FY2021 | Sep 30, 2021 | $85.32M | -7.4% |
| Q2 FY2021 | Jun 30, 2021 | $104.96M | +37.5% |
| Q1 FY2021 | Mar 31, 2021 | $81.26M | +46.0% |
| Q4 FY2020 | Dec 31, 2020 | $107.41M | +46.4% |
| Q3 FY2020 | Sep 30, 2020 | $92.15M | +3.3% |
| Q2 FY2020 | Jun 30, 2020 | $76.34M | -18.1% |
| Q1 FY2020 | Mar 31, 2020 | $55.66M | -36.9% |
| Q4 FY2019 | Dec 31, 2019 | $73.37M | +90.1% |
| Q3 FY2019 | Sep 30, 2019 | $89.20M | -13.7% |
| Q2 FY2019 | Jun 30, 2019 | $93.25M | -10.3% |
| Q1 FY2019 | Mar 31, 2019 | $88.26M | +13.3% |
| Q4 FY2018 | Dec 31, 2018 | $38.60M | -67.3% |
| Q3 FY2018 | Sep 30, 2018 | $103.37M | +26.3% |
| Q2 FY2018 | Jun 30, 2018 | $104.00M | +26.5% |
| Q1 FY2018 | Mar 31, 2018 | $77.90M | +21.9% |
| Q4 FY2017 | Dec 31, 2017 | $118.16M | +48.1% |
| Q3 FY2017 | Sep 30, 2017 | $81.82M | – |
| Q2 FY2017 | Jun 30, 2017 | $82.19M | – |
| Q1 FY2017 | Mar 31, 2017 | $63.89M | – |
| Q4 FY2016 | Dec 31, 2016 | $79.78M | – |
See a number that looks wrong?